Photo: open.spotify.com
Apr 21, 2026, 14:44
Continuing the Conversation on Factor VIII – EAHAD
European Association for Haemophilia and Allied Disorders (EAHAD), shared a post on LinkedIn:
”Continuing the conversation on Factor VIII!
As innovations such as emicizumab, rebalancing agents, and gene therapy continue to transform care, what is the place of FVIII today, and where is it heading next?”
Stay updated with Hemostasis Today.
-
May 18, 2026, 16:35Abdurrahmaan Ali Suei Elbuzidi: What is the Optimal Anticoagulation Monitoring Target in ECMO?
-
May 18, 2026, 16:34Serah N. Gathu: Gaining Valuable Updates on ACS Management at the Africa STEMI Conference
-
May 18, 2026, 16:34Mahmoud Alhariri: Apixaban in Hemodialysis-Treated Kidney Failure With Newly Diagnosed AF
-
May 18, 2026, 16:33Dimitrios Kontothanassis: The Role of Thermal Ablation in GSV Reflux Treatment – LIVE 2026
-
May 18, 2026, 16:32Michael Lichardi: New Publication on Complex Anticoagulation Management in Critical Care
-
May 18, 2026, 16:28Reza Shojaei: The Global Plasma-to-Ig Supply Chain
-
May 18, 2026, 16:01Abdul Mannan: The Hardest Conversations in Myelofibrosis
-
May 18, 2026, 15:57Bridging Innovation and Access at the WFH 2026 World Congress – South African Haemophilia Foundation
-
May 18, 2026, 15:55Pierre François Sabouret: Network Meta-Analysis of Antithrombotic Therapy in Ischemic Stroke Patients